breast cancer

April 20, 2017

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

By VUMC News and Communications
March 30, 2017

Horn to lead lung cancer combination therapy trial

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.

By VUMC News and Communications
March 30, 2017

Research support

DS Services of America Inc. recently presented a $100,000 gift to Vanderbilt-Ingram Cancer Center (VICC) to support breast cancer research.

By VUMC News and Communications
March 23, 2017

Breast cancer program lands new research grants

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.

By VUMC News and Communications
color-enhanced cross section of tumor tissue
January 16, 2017

Softening tumor tissue could aid cancer treatments

Tumors cause the intracellular material surrounding them to stiffen. Softening this protective layer could make existing cancer treatments more effective, according to new research.

By VUMC News and Communications
November 18, 2016

Targeting the “un-targetable”

A novel drug that targets the protein RSK blocked aggressive breast cancers from metastasizing in an animal model.

By VUMC News and Communications
September 29, 2016

BMI genotype and breast cancer risk

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults.
By Paul Govern
September 22, 2016

National Lymphedema Network honors VUMC research efforts

Lymphedema research conducted at Vanderbilt University Medical Center (VUMC) to better understand patient risk for this chronic condition and treatment responses received recognition at an international conference.
By Tom Wilemon
September 9, 2016

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.
By Leigh MacMillan
August 26, 2016

New breast cancer driver

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers.
By Leigh MacMillan
July 20, 2016

Breast cancer: finding the smoking gun

A new method developed at Vanderbilt may help “inventory” all tumor-promoting genes.
By Bill Snyder
July 6, 2016

VICC researchers to study reasons for high breast cancer incidence and mortality rates among African-American women

A cancer research consortium headed by investigators at Vanderbilt-Ingram Cancer Center and two other institutions have received $12 million in federal funding to help determine why African-American women die at a higher rate and have more aggressive breast cancer than white women.
By VUMC News and Communications
April 21, 2016

Study explores how some breast cancers resist treatment

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
By VUMC News and Communications
1 … 4 5 6 7 8 … 11